Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-1035

Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-1035-1mg 1mg 3090
GMP-Bios-INN-1035-10mg 10mg Inquiry
GMP-Bios-INN-1035-100mg 100mg Inquiry
GMP-Bios-INN-1035-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Tucotuzumab Celmoleukin biosimilar, Fusion Protein, Tucotuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with human IL2 (interleukin 2, IL-2) Pr21-153
INN Name Tucotuzumab Celmoleukin
TargetEPCAM
FormatFusion Protein
DerivationHumanized
Species Reactivityhuman
CH1 IsotypeIgG1 - nd
VD LCIgG1 - nd
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesMerck Serono International S.A. (Geneva Switzerland)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0